Guides May 18, 2026

Hexarelin: The Most Potent GHRP and the One Ipamorelin Was Built to Replace

Hexarelin may have been the most potent GHRP of its generation, but off-target hormone release, rapid desensitization, and a failed development path explain why newer peptides like ipamorelin replaced it.

Hexarelin is one of the best examples in peptide pharmacology of why more potent does not always mean more useful.

For a while, it looked like an ideal growth-hormone-releasing peptide:

very strong GH release
good chemical stability
real clinical investigation
and even a genuinely unusual cardiovascular research story

But in the end, hexarelin became more important as a historical predecessor than as a successful therapy.

That is largely because it exposed two problems the next generation of GHRPs tried to solve:

poor selectivity
and rapid desensitization

If ipamorelin is the “clean” GHRP most people now hear about, hexarelin is one of the clearest explanations for why the class moved in that direction.

What hexarelin is

Hexarelin is a synthetic hexapeptide in the growth-hormone-releasing peptide (GHRP) family.¹²

The sequence commonly reported for hexarelin is:

His-D-2-methyl-Trp-Ala-Trp-D-Phe-Lys-NH2³

It was developed as a more potent and more stable descendant of earlier GHRPs such as GHRP-6.³

And by the standards of its era, it succeeded at that.

Why hexarelin mattered so much in the first place

Human endocrine studies in the 1990s showed that hexarelin was an extremely strong GH secretagogue.

The 1996 JCEM dose-response study from Massoud, Hindmarsh, and Brook found that hexarelin caused clear dose-dependent increases in:

growth hormone
cortisol
and prolactin in healthy adults¹

The 1997 Peptides paper from Arvat et al. confirmed that hexarelin robustly stimulated:

GH
prolactin
ACTH
and cortisol in humans²

That first part explains the early excitement.

Hexarelin was not weak.

If anything, it was too good at hitting more than one endocrine output.

Problem 1: hexarelin was not selective

This was the first big limitation.

The same endocrine papers that made hexarelin look powerful also made it clear that it was not a “GH-only” tool.

Massoud et al. showed that the GH response was accompanied by significant rises in cortisol and prolactin.¹

Arvat et al. similarly reported significant stimulation of ACTH, cortisol, and prolactin in addition to GH.²

That matters because from a drug-development perspective, the goal was not just “make the pituitary do something dramatic.”

The goal was to stimulate growth-hormone pathways without dragging too much of the HPA axis and other pituitary outputs along with it.

Hexarelin never really solved that.

So even before desensitization enters the picture, you already have one major reason the class kept evolving:

hexarelin was potent, but not clean.

Problem 2: rapid tachyphylaxis

This was the more decisive problem.

Repeated exposure to hexarelin did not preserve the same GH response over time.

The 1996 study by Borson-Chazot et al. on repeated administration of hexarelin showed that the GH response attenuated with repeated exposure, consistent with a tachyphylaxis / desensitization pattern.⁴

Later in vitro work made the receptor-level explanation even clearer. A 2003 European Journal of Endocrinology paper reported rapid desensitization of the growth-hormone secretagogue receptor to hexarelin within minutes of repeat exposure in cellular assays.⁵

Those two facts together are the real teaching point:

the problem was visible in human physiology
and it also made mechanistic sense at the receptor-signaling level

That is why people often talk about hexarelin as a compound that stops working well with continuous use.

The exact time course depends on the context and the source you read, but the broader conclusion is stable:

hexarelin is poorly suited to sustained chronic GH stimulation because responsiveness fades.

That is a serious development problem, not a minor inconvenience.

This is the context that makes ipamorelin make sense

Once you understand the hexarelin problem, the logic behind ipamorelin becomes much clearer.

The next generation of GHRP development was not just trying to make a secretagogue that worked.

Hexarelin already worked.

It was trying to make one that:

preserved useful GH release
produced far less ACTH / cortisol / prolactin spillover
and behaved more predictably with repeated dosing

That is why ipamorelin became important conceptually.

It was not simply “another peptide in the same family.”

It represented a design response to the liabilities that compounds like hexarelin exposed.

In other words:

hexarelin helped define the problem
ipamorelin helped define the attempted fix

The genuinely distinctive part: CD36

If the story ended there, hexarelin would still be historically important.

But it has one additional feature that makes it genuinely unusual:

hexarelin also binds CD36.

This is not just a niche footnote.

The 2002 Circulation Research paper by Bodart et al. identified CD36 as a cardiac receptor mediating hexarelin’s cardiovascular actions.⁶

That is a very different story from the classic pituitary ghrelin-receptor framing.

The paper showed that cardiovascular responses to hexarelin in the heart were linked to CD36, and that this effect disappeared in models lacking functional CD36.⁶

That finding opened up an entirely different line of thinking:

hexarelin might not only be a GH secretagogue, but also a compound with GH-independent cardioprotective actions.

Why the cardiovascular work attracted attention

Subsequent cardiac work kept that idea alive for a while.

Clinical and translational studies reported that hexarelin could improve left ventricular performance or produce favorable cardiac effects in people with severe ventricular dysfunction, effects not fully explained by GH release alone.⁷⁸

Reviews of the field emphasized that hexarelin’s cardiac effects likely reflected a combination of:

growth-hormone secretagogue receptor biology
and CD36-mediated mechanisms³

That is what makes hexarelin scientifically richer than a simple “old GH peptide that fell out of favor.”

It is one of the few compounds in this class with a real second-receptor story that mattered.

Why it still never became an approved therapy

This is the bottom line.

Hexarelin had:

strong GH potency
a real endocrine literature
interesting cardiovascular biology
and actual clinical investigation

But none of that was enough.

The reasons are not hard to understand in hindsight:

1. Off-target endocrine effects

It increased cortisol, ACTH, and prolactin in addition to GH.¹²

That makes it harder to position as a clean long-term therapy.

2. Desensitization

Repeated exposure reduced response, which is exactly what you do not want in a chronic GH-targeted drug.⁴⁵

3. Better directional successors appeared

Once the field moved toward more selective molecules like ipamorelin, hexarelin started to look more like a transitional compound than an endpoint.

4. The cardiovascular angle was interesting, but not enough

The CD36 work made hexarelin unique scientifically, but uniqueness is not the same thing as a viable approval path.

In practice, hexarelin became an important research compound and a useful piece of GHRP history rather than an approved medicine.

The best way to understand hexarelin today

Hexarelin is probably best understood as:

the most potent GHRP of its generation
one of the clearest examples of why potency alone is not enough
and the peptide that helps explain why the class eventually moved toward selectivity

That is what makes it still worth covering.

It is not just a forgotten peptide.

It is a pharmacology lesson:

the compounds that shape a field are not always the ones that ultimately win it.